AMYLOIDOGENIC TRANSTHYRETIN (ATTR) AMYLOIDOSIS
Clinical trials for AMYLOIDOGENIC TRANSTHYRETIN (ATTR) AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AMYLOIDOGENIC TRANSTHYRETIN (ATTR) AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AMYLOIDOGENIC TRANSTHYRETIN (ATTR) AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a daily pill keep a rare heart disease in check for the long haul?
Disease control Not yet recruitingThis study tests the long-term safety and tolerability of acoramidis, an oral medication that stabilizes the transthyretin protein, in people newly diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that can lead to heart failure. Participants who complete…
Matched conditions: AMYLOIDOGENIC TRANSTHYRETIN (ATTR) AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New PET scan could spot hidden heart disease
Diagnosis Not yet recruitingThis study tests whether a special PET-CT scan using a drug called evuzamitide can detect signs of cardiac amyloidosis in people whose standard heart scans were unclear but who have high levels of a blood marker called TAD1. About 25 adults with heart failure or a genetic risk fo…
Matched conditions: AMYLOIDOGENIC TRANSTHYRETIN (ATTR) AMYLOIDOSIS
Sponsor: Lorena Saelices • Aim: Diagnosis
Last updated Jun 27, 2026 12:09 UTC